These results provide a strong rationale for further studies of the role of MCT2 in PCa and other tumor types, where it may provide new opportunities as either a biomarker for disease tissue or a therapeutic target similar to the recent developments for other members of the monocarboxylate transporter family. Here, SLC16A7 is linked to neoplasm.